Особливості медикаментозного впливу патогенетичної та базисної терапії ревматоїдного артриту на стан нирок

L. A. Zub, S. V. Roborchuk

Анотація


У статті наведено сучасні уявлення щодо впливу патогенетичної та базисної терапії ревматоїдного артриту на стан нирок.


Ключові слова


ревматоїдний артрит; нирки; базисна терапія; патогенетична терапія

Посилання


Balabanova R. Rheumatoid arthritis: diagnosis, treatment. Vrach. 2012; 5: 6-9 (in Russian).

Nasonov E.L. Clinical recommendations. Rheumatology. Moskow; 2008 (in Russian).

Nikulin B.A. Evaluation and correction of immune status. Moskow: GEOTAR-Media; 2007 (in Russian).

Ovchinnikova L.K., Ovchinnikova E.A. Rheumatoid arthritis. Rossiyskie apteki. 2009; 5: 20-21 (in Russian).

Goekoop-Ruiterman Y.P., Vries-Bouwstra de J.K., Allaart C.F. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2007; 146: 406-415.

Al-Turkmani M.R., Law T., Narla A. Difficulty measuring methotrexate in a patient with highdose methotrexate-induced nephrotoxicity. Clin. Chem. 2010; 56 (12): 1792-1794.

Kremer J.M., Genant H.K., Moreland L.W. Effects of abatacept in patients with methotrexate–resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865-876.

Kirwan J.R., Bijlsma J.W., Boers M. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007.

Nakamura T., Higashi S., Tomoda K. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2012; 51: 2064-2069.

First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. By the Latin American Rheumatology Associations of the Pan-American League of Associations for Rheumatology (PANLAR) and the Grupo Latinoamericano de Estudio de Artritis Reumatoide (GLADAR). Rheumatology. 2006; 45: 117-122.

Kapetanovich M.C., Saxne T., Sjoholm A. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatol. 2006; 45: 106-111.

Nixon R., Bansback N., Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 2007; 46: 1140-1147.

O'Shea J., Laurence A., McInnes I. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nature Reviews Rheumatology. 2013; 9: 173-182.

Pisetsky D.S., Ward M.M. Advances in the treatment of inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 2012; 26 (2): 251-261.

Finckh A., Bansback N., Marra C.A. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease modifying antirheumatic drugs, or biologic agents. A cost-effectiveness analysis. Ann Intern Med. 2009; 151: 612-621.

Jacobsson L.T., Turesson C., Nilsson J.A. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 670-675.

Wolfe F., Michaud K. Duration of Use of Anti-TNF Therapy in Rheumatoid Arthritis. [Presented at the 2007 American College of Rheumatology Scientific Meeting], (Boston, 10-11 November 2007). Arthritis Rheum. 2007.


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24061/100525

Copyright (c) 2017 L. A. Zub, S. V. Roborchuk

Технічний редактор журналу, к.мед.н. М. Степанченко, 2015-2017